Jacksonville, Fla.– Dr. Kenneth Savin, Chief Scientist at Redwire Corporation, has been named to the 2025 TIME100 Health list, which honors the most influential people in global health. The recognition highlights Dr. Savin’s groundbreaking contributions to space-based biomedical research and his efforts to transform pharmaceutical development through microgravity innovation.
TIME’s annual list spotlights leaders advancing the future of health and medicine, and Dr. Savin earned his place for his unique role in leveraging the International Space Station (ISS) as a platform for biomedical discovery. Under his leadership, Redwire has conducted a series of firsts in space, including the bioprinting of the first human knee meniscus and the first live human cardiac tissue using its BioFabrication Facility aboard the ISS. These achievements mark significant steps toward developing next-generation tissue therapies and organ transplantation technologies.
Dr. Savin has also spearheaded collaborations with major pharmaceutical companies, including Eli Lilly and Bristol Myers Squibb, to use Redwire’s PIL-BOX lab in orbit to study protein crystallization. These investigations aim to enhance drug development across a range of conditions, from heart disease and bone loss to infectious diseases and neurological disorders.
“I am deeply honored to be recognized as one of the TIME100’s most influential figures in health for 2025,” said Dr. Savin. “Microgravity research is unlocking scientific opportunities that aren’t possible on Earth, and we’re just beginning to understand its vast potential to revolutionize medicine.”
With over two decades in the pharmaceutical industry, Dr. Savin previously led R&D teams at Eli Lilly and directed five ISS-based investigations. He later served as Senior Director of In-Space Production Applications at the Center for the Advancement of Science In Space (CASIS), where he worked closely with NASA to establish the In Space Production and Applications program.
At Redwire, Dr. Savin continues to drive innovation in space biotech, positioning the company at the forefront of the evolving space economy while helping advance scientific breakthroughs that could dramatically improve health outcomes on Earth.
